Login / Signup
Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054.
Alexander Eggermont
Michal Kicinski
Stefan Suciu
Published in:
Journal for immunotherapy of cancer (2022)
Keyphrases
</>
phase iii
phase ii
open label
clinical trial
early stage
double blind
placebo controlled